Replies to post #223746 on Avid Bioservices Inc (CDMO)

[BioBS2012]

can somebody with a good relationship with IR ask them who will be reimbursing for opdivo, and under what document?

i don't believe they'll respond to me.

If the study is run in the US and Opdivo is approved for the indication (not yet approved for non-squamous NSCLC), then the patients insurance would re-imburse, but certainly not off-label. Don't know what the situation would be in the EU.
Alternatively someone like MSK could provide a grant to cover cost of Opdivo - just a thought.

Cheers.